KemPharm, Inc. (KMPH): Price and Financial Metrics


KemPharm, Inc. (KMPH)

Today's Latest Price: $0.19 USD

0.00 (2.51%)

Updated May 29 5:20pm

Add KMPH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

KMPH Stock Summary

  • Kempharm Inc's market capitalization of $12,034,561 is ahead of merely 6.65% of US-listed equities.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -0.15 for Kempharm Inc; that's greater than it is for only 6.86% of US stocks.
  • The volatility of Kempharm Inc's share price is greater than that of 93.62% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to KMPH, based on their financial statements, market capitalization, and price volatility, are AAOI, FBIO, MXL, VECO, and LJPC.
  • Visit KMPH's SEC page to see the company's official filings. To visit the company's web site, go to kempharm.com.
KMPH Daily Price Range
KMPH 52-Week Price Range

KMPH Stock Price Chart More Charts


KMPH Price/Volume Stats

Current price $0.19 52-week high $2.00
Prev. close $0.18 52-week low $0.12
Day low $0.18 Volume 908,756
Day high $0.19 Avg. volume 2,800,915
50-day MA $0.24 Dividend yield N/A
200-day MA $0.46 Market Cap 12.33M

KemPharm, Inc. (KMPH) Company Bio


KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of prodrugs to treat high need areas of pain, ADHD and other CNS disorders. The company was founded in 2006 and is based in Coralville, Iowa.


KMPH Latest News Stream


Event/TimeNews Detail
Loading, please wait...

KMPH Latest Social Stream


Loading social stream, please wait...

View Full KMPH Social Stream

Latest KMPH News From Around the Web

Below are the latest news stories about Kempharm Inc that investors may wish to consider to help them evaluate KMPH as an investment opportunity.

KemPharm Receives Day-74 Letter for KP415 NDA

KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the Company has received a filing communication from the U.S. Food and Drug Administration (FDA), commonly known as the “Day-74 Letter.” The Day-74 Letter stated that the New Drug Application (NDA) for KP415 is sufficiently complete to permit a substantive review by the FDA, and that the target goal date under the Prescription Drug User Fee Act (PDUFA) is March 2, 2021. In addition, the Day-74 Letter indicated that the FDA is not currently planning to hold an advisory committee to discuss the KP415 NDA.

Yahoo | May 19, 2020

KemPharm Reports First Quarter 2020 Financial Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m. ET Corporate and Regulatory Highlights: KP415 NDA filing accepted by FDA on.

Yahoo | May 12, 2020

KemPharm to Report First Quarter 2020 Financial Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Tuesday, May 12, 2020, 5:00 p.m. ET CELEBRATION, Fla., May 06, 2020 -- KemPharm, Inc. (Nasdaq:.

Yahoo | May 6, 2020

NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital

KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its investigational product candidate, KP415. Per the definitive collaboration and license agreement (the “License Agreement”) between KemPharm and an affiliate of Gurnet Point Capital (GPC), KemPharm is eligible to receive a regulatory milestone payment of $5 million within thirty (30) days following FDA acceptance of the KP415 NDA.

Yahoo | May 4, 2020

KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it has submitted a New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for its investigational product candidate, KP415, to the U.S. Food and Drug Administration (FDA). KP415 is KemPharm’s product candidate for the treatment of attention deficit hyperactivity disorder (ADHD) which contains serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH).

Yahoo | March 2, 2020

Read More 'KMPH' Stories Here

KMPH Price Returns

1-mo -36.67%
3-mo -37.29%
6-mo -57.23%
1-year 1,087.50%
3-year -95.63%
5-year -98.53%
YTD -49.91%
2019 -78.69%
2018 -56.05%
2017 37.29%
2016 -85.15%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8978 seconds.